Overview

Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI)

Status:
Completed

Trial end date:
2004-09-01

Target enrollment:

Participant gender:

Summary

Serious infections caused by resistant bacteria are becoming more of a medical problem throughout the world. This study will measure how well TD-6424 (Telavancin) can control infections and whether the drug is safe to give to patients.

Phase:

Phase 2

Details

Lead Sponsor:

Cumberland Pharmaceuticals
Theravance Biopharma Antibiotics, Inc.

Treatments:

Penicillins
Telavancin
Vancomycin